CERUS CORP (CERS) Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
Cerus Corporation NASDAQ:CERS Healthcare · Medical - Devices
Mkt Cap $459.48M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Cerus Corporation to Release Third Quarter 2026 Financial Results on November 2, 2026
Cerus Corporation will release its third quarter 2026 financial results on Monday, November 2, 2026, after market close.
Management will host a conference call and webcast at 4:30 P.M. ET to discuss results and provide a business overview and outlook, with a replay available through November 23, 2026.
This is a scheduling announcement only; no financial results or guidance are included.
• 13d ago AI analysis › Press Release
Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting
Cerus will host an industry workshop on real-world experience with INTERCEPT Platelets and INTERCEPT Fibrinogen Complex at the AABB Annual Meeting in Atlanta, October 17-19.
The program includes oral presentations on pathogen reduction in blood donations and liver transplantation, plus nine poster presentations covering the INT200 LED Illuminator and two decades of European hemovigilance data.
The release is promotional scientific visibility with no new clinical, regulatory, or financial information; the workshop focuses on Grady Health System's implementation experience.
• 18d ago AI analysis › Press Release ● Major ⚠ 2
Cerus Corporation Announces Second Quarter 2026 Financial Results
Cerus reported Q2 2026 total revenue of $63.3 million, with product revenue increasing 10% year-over-year to $57.4 million driven by growth across all product categories.
The company achieved a significant operational improvement, narrowing its net loss to $2.9 million from $5.7 million in the prior year and delivering positive Non-GAAP Adjusted EBITDA of $3.0 million.
Management raised the lower end of full-year 2026 product revenue guidance to $229 million and increased its IFC sales outlook to $23-$25 million, reflecting anticipated growth of 40% to 50%.
• 3mo ago AI analysis › Press Release
Cerus Corporation to Release Second Quarter 2026 Financial Results on July 30, 2026
Cerus Corporation announced it will release its second quarter 2026 financial results on July 30, 2026, after the market closes.
Management will host a conference call and webcast at 4:30 P.M. ET to discuss the results and provide a business outlook.
A replay of the call will be available on the company's website approximately three hours after the event through August 20, 2026.
• 3mo ago AI analysis › Press Release
Cerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT Congress
Cerus Corporation announced it will host a lunch symposium and present multiple abstracts at the 39th International ISBT Congress in Kuala Lumpur from June 20-24, 2026.
The presentations will highlight how blood centers globally use INTERCEPT technology to enhance safety and efficiency, featuring innovations like the INT200 illuminator and extended platelet shelf-life data from Thailand.
Additionally, an abstract from China will address bacterial contamination risks in platelet components to underscore the value of pathogen inactivation strategies.
• 4mo ago AI analysis › Press Release
Cerus Corporation Closes New Debt Facility of Up to $110 Million
Cerus Corporation closed a new debt facility with MidCap Financial providing up to $110 million in total capacity.
The facility consists of a 5-year term loan (initially $35 million, with up to $30 million more available) and a 5-year revolving credit line of up to $45 million.
The refinancing retires an existing $65 million term loan, extends maturities, and is expected to save up to $3.5 million annually in cash interest expense.
• 4mo ago AI analysis › Press Release ⚠ 4
Bradley L. Radoff Announces Intent to Withhold Votes from Chair and CEO William Greenman and Director Ann Lucena
Significant shareholder Bradley L. Radoff announced he will withhold votes for Chair/CEO William Greenman and Director Ann Lucena at Cerus’ 2026 annual meeting on June 2.
Radoff cites a 10-year total shareholder return of -50.8% and a near-doubling of the share count from ~102 million to ~200 million as evidence of value destruction and excessive dilution.
He also criticizes the board’s classified structure and the planned transition of Greenman to Executive Chair, calling for greater accountability and a focus on profitability.
• 5mo ago AI analysis › Press Release ● Major
Cerus Corporation Announces First Quarter 2026 Financial Results
Cerus reported Q1 2026 total revenue of $59.9 million, a 23% increase over the prior year, driven primarily by a 24% rise in product revenue to $53.7 million.
The company raised its full-year 2026 product revenue guidance to $227 million-$231 million, reflecting 10% to 12% year-over-year growth, and noted positive adjusted EBITDA of $4.0 million.
Cerus also announced a leadership transition, with President and CEO William “Obi” Greenman becoming executive chairman and COO Vivek Jayaraman succeeding him as CEO effective July 1, 2026.
• 6mo ago AI analysis › 
